Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 328 4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

Mart41 Aug. 19 at 4:10 PM

$OCGN probablement le meilleur investissement de toute une vie 💪🚀

0 · Reply

ChiefNC9 Aug. 19 at 3:43 PM

$OCGN well that was fun while it lasted

1 · Reply

VinEuro Aug. 19 at 3:41 PM

$OCGN Can’t even hold 😂 What’s this pump? Holding strong, together with my bagholders ✨

0 · Reply

Bedtimereminder Aug. 19 at 3:40 PM

$OCGN 👀 Short squeeze setup? ~30%+ of the float reportedly short. Fresh Phase 3 clearance, biotech momentum is back, and now we just need VOLUME. If $1.46 breaks with real volume, this could get interesting fast. 🚀 Let the shorts fuel the move. 🔥 #OCGN #ShortSqueeze #Biotech

0 · Reply

Affliction99 Aug. 19 at 3:34 PM

$OCGN remember to vote "For''

0 · Reply

Kgtrades Aug. 19 at 3:32 PM

$OCGN shorts are stupid cockroaches!

0 · Reply

scalp_scalpnyc Aug. 19 at 3:19 PM

$OCGN 50+

0 · Reply

CasaDePapel Aug. 19 at 3:07 PM

$OCGN pump harder you fake bulls!!! This drops back soon

1 · Reply

marameo Aug. 19 at 3:02 PM

$OCGN forza che vogliamo vederci tutti molto chiaro🤓

1 · Reply

dgiudice Aug. 19 at 2:55 PM

$OCGN this is the weakest position of all. lol. Reeks of desperation. You’re better off hoping their treatments cause cancer. lol.

3 · Reply

Ocugen Proxy statement: Proxy filing

Aug 11, 2026, 1:00 PM EDT - 7 days ago

Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Ocugen Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Ocugen Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Ocugen Quarterly report: Q2 2026

2026-08-06T12:11:23.000Z - 13 days ago

Ocugen reports Q2 EPS (7c), consensus (5c)

Aug 6, 2026, 7:02 AM EDT - 13 days ago

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Jul 31, 2026, 7:02 AM EDT - 19 days ago

Ocugen to Participate in Upcoming August Investor Conferences

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Ocugen Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Ocugen Proxy statement: Proxy filing

2026-07-29T11:51:46.000Z - 21 days ago

Ocugen granted RMAT designation for OCU410

Jul 29, 2026, 7:01 AM EDT - 21 days ago

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Jul 28, 2026, 4:01 PM EDT - 21 days ago

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Ocugen Proxy statement: Proxy filing

2026-07-13T11:35:36.000Z - 5 weeks ago

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

Jul 13, 2026, 7:02 AM EDT - 5 weeks ago

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Jul 10, 2026, 10:00 AM EDT - 5 weeks ago

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Ocugen to Participate in Upcoming July Industry Conferences

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Ocugen Transcript: AGM 2026

Jun 4, 2026, 2:30 PM EDT - 2 months ago

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Jun 2, 2026, 7:03 AM EDT - 2 months ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

2026-05-27T11:37:17.000Z - 3 months ago

Ocugen price target lowered to $11 from $12 at Canaccord

May 26, 2026, 10:30 AM EDT - 3 months ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 14, 2026, 4:30 PM EDT - 3 months ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 13, 2026, 7:02 AM EDT - 3 months ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-05T13:15:52.000Z - 3 months ago

Ocugen reports Q1 EPS (6c), consensus (5c)

May 5, 2026, 8:32 AM EDT - 3 months ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:12 AM EDT - 3 months ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

2026-05-04T20:16:05.000Z - 3 months ago

Ocugen announces private offering of $115M of convertible senior notes

May 4, 2026, 4:01 PM EDT - 3 months ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Apr 29, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Apr 23, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

2026-04-01T11:56:15.000Z - 5 months ago

Ocugen completes dosing in GARDian3 trial

Apr 1, 2026, 7:02 AM EDT - 5 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

2026-03-25T13:20:15.000Z - 5 months ago

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T10:11:21.000Z - 5 months ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Ocugen Press release: Study update

2026-03-24T11:55:27.000Z - 5 months ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Mar 24, 2026, 7:45 AM EDT - 5 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 23, 2026, 7:02 AM EDT - 5 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

2026-03-17T11:30:27.000Z - 5 months ago

Ocugen initiated with a Buy at Canaccord

2026-03-11T10:40:53.000Z - 5 months ago

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:10:53.000Z - 5 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Earnings release: Q4 2025

Mar 4, 2026, 8:15 AM EST - 6 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 7:02 AM EST - 6 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Feb 9, 2026, 7:02 AM EST - 6 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Jan 23, 2026, 8:00 AM EST - 7 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 7 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Press release: Study result

Jan 15, 2026, 8:15 AM EST - 7 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 13, 2026, 7:00 AM EST - 7 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 12, 2026, 6:30 AM EST - 7 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 9, 2026, 7:02 AM EST - 7 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Dec 10, 2025, 9:20 AM EST - 9 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 20, 2025, 7:02 AM EST - 9 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 6:30 AM EST - 10 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Sep 25, 2025, 9:30 AM EDT - 11 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 15, 2025, 6:03 AM EDT - 1 year ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 2, 2025, 7:02 AM EDT - 1 year ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Aug 13, 2025, 6:27 AM EDT - 1 year ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 12, 2025, 3:45 PM EDT - 1 year ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 1 year ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:25 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mart41 Aug. 19 at 4:10 PM

$OCGN probablement le meilleur investissement de toute une vie 💪🚀

0 · Reply

ChiefNC9 Aug. 19 at 3:43 PM

$OCGN well that was fun while it lasted

1 · Reply

VinEuro Aug. 19 at 3:41 PM

$OCGN Can’t even hold 😂 What’s this pump? Holding strong, together with my bagholders ✨

0 · Reply

Bedtimereminder Aug. 19 at 3:40 PM

0 · Reply

Affliction99 Aug. 19 at 3:34 PM

$OCGN remember to vote "For''

0 · Reply

Kgtrades Aug. 19 at 3:32 PM

$OCGN shorts are stupid cockroaches!

0 · Reply

scalp_scalpnyc Aug. 19 at 3:19 PM

$OCGN 50+

0 · Reply

CasaDePapel Aug. 19 at 3:07 PM

$OCGN pump harder you fake bulls!!! This drops back soon

1 · Reply

marameo Aug. 19 at 3:02 PM

$OCGN forza che vogliamo vederci tutti molto chiaro🤓

1 · Reply

dgiudice Aug. 19 at 2:55 PM

$OCGN this is the weakest position of all. lol. Reeks of desperation. You’re better off hoping their treatments cause cancer. lol.

3 · Reply

rooferboyuk Aug. 19 at 2:53 PM

$OCGN who's seen moderna today.

0 · Reply

HowULuvThis Aug. 19 at 2:50 PM

$OCGN Surely if you got some shares around this time when everyone was gobbling them up...you're in the green👊😎👊

0 · Reply

SGimvesting Aug. 19 at 2:40 PM

$OCGN somebody ALWAYS knows something

0 · Reply

Gr8peApe Aug. 19 at 2:39 PM

$OCGN $$$

0 · Reply

Manuelitos Aug. 19 at 2:33 PM

$OCGN

0 · Reply

SGimvesting Aug. 19 at 2:17 PM

$OCGN oh I see. They’re trying to raise the price before my doublewide sells.

1 · Reply

Hrumph63 Aug. 19 at 2:07 PM

$OCGN Increasing authorized shares is just the setup for the next dilution. Pretending otherwise is pure cope. You’ve been drinking the CEO’s Ocujuice so long you think endless raises and “multiple BLAs” talk somehow erase 7 years of missed timelines and massive share count growth. Dilution is still dilution. Calling it “de-risking” doesn’t change the math.

0 · Reply

dgiudice Aug. 19 at 2:03 PM

$OCGN We can wait it all out. You guys? Not so much.

1 · Reply

dmac937 Aug. 19 at 2:00 PM

$OCGN

0 · Reply